rs7528684 — FCRL3 -169C>T

Promoter variant in FCRL3 that alters NF-κB binding and elevates FCRL3 expression on B cells and regulatory T cells, increasing susceptibility to rheumatoid arthritis, Graves' disease, systemic lupus erythematosus, and Hashimoto's thyroiditis

See your personal result for FCRL3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FCRL3 — The Promoter Switch That Amplifies B-Cell Autoimmunity

The FCRL311 FCRL3
Fc receptor-like 3, a member of the immunoglobulin superfamily expressed at high levels on B cells and regulatory T cells; encodes a transmembrane receptor with multiple immunoreceptor tyrosine-based inhibitory and activation motifs (ITIMs and ITAMs) gene produces a surface receptor that modulates how B cells integrate activating and inhibitory signals. Unlike the classical Fc receptors that bind antibody constant regions to clear immune complexes, FCRL3 is expressed constitutively on B cells and plays a role in setting the threshold for B cell activation and autoantibody production. At position -169 in its promoter region, a C-to-T substitution (rs7528684) acts as a molecular volume knob: one variant drives higher FCRL3 transcription, the other does not. Which side of that switch a person carries matters for risk across multiple autoimmune diseases.

The variant is described in the literature as -169C>T using coding-strand notation (FCRL3 is transcribed from the minus strand of chromosome 1). In genome file notation (plus strand), the alleles are A and G, where the G allele corresponds to the coding C allele — the variant associated with higher FCRL3 expression and elevated autoimmune risk.

The Mechanism

The -169 position lies within an NF-κB22 NF-κB
nuclear factor kappa-light-chain-enhancer of activated B cells; a master transcription factor family that controls genes involved in immune activation, inflammation, and cell survival binding site in the FCRL3 promoter. The C allele (plus-strand G) creates a binding motif with higher affinity for NF-κB, leading to greater transcriptional activation of FCRL3 in B cells and regulatory T cells (Tregs). In the original discovery study, individuals carrying the risk genotype showed measurably higher FCRL3 protein expression on their B cells and produced greater quantities of autoantibodies — the antibodies that attack self-tissues in diseases like rheumatoid arthritis and Hashimoto's thyroiditis.

FCRL3 overexpression on Tregs is particularly significant. Regulatory T cells normally suppress autoreactive immune responses; elevated FCRL3 on Tregs appears to impair their suppressive capacity, likely by modulating FOXP3 expression. A 2026 study confirmed that CC genotype carriers show downregulated FOXP3 and IL-3533 CC genotype carriers show downregulated FOXP3 and IL-35
FOXP3 is the master transcription factor of regulatory T cells; IL-35 is an anti-inflammatory cytokine produced by Tregs that suppresses effector T cell responses; both are reduced in CC carriers, disrupting immune tolerance alongside elevated FCRL3, creating a dual loss of tolerance mechanisms: hyperactive B cells producing autoantibodies combined with impaired Treg suppression.

The Evidence

The variant was first identified by Kochi et al. in Nature Genetics (2005)44 Kochi et al. in Nature Genetics (2005)
Kochi Y, Yamada R, Suzuki A et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nature Genetics 37:478–485 in a Japanese cohort of 830 RA cases and 658 controls, with an odds ratio of 2.15 (P=8.5×10⁻⁷) for rheumatoid arthritis. The same study found associations with Graves' disease (autoimmune hyperthyroidism) and SLE, positioning FCRL3 as a pleiotropic autoimmune susceptibility gene rather than a disease-specific variant.

An updated meta-analysis of 34 case-control studies55 updated meta-analysis of 34 case-control studies
Yang Y, Su X, Zhang K, Zhou R. The Fc receptor-like 3 gene polymorphisms and susceptibility to autoimmune diseases: an updated meta-analysis. Autoimmunity 46:547–558, 2013 confirmed significant associations of rs7528684 with RA, Graves' disease, and type 1 diabetes. Carriers of TC or TT genotypes showed approximately 9% lower odds of autoimmune diseases compared to CC carriers (OR=0.91, 95% CI 0.85–0.97) — indicating that having even one copy of the lower-expression T allele (plus-strand A) provides partial protection against CC-level risk.

For rheumatoid arthritis specifically, a Chinese case-control study of 630 RA patients and 696 controls, combined with meta-analysis66 Chinese case-control study of 630 RA patients and 696 controls, combined with meta-analysis
Lin X, Zhang Y, Chen Q. FCRL3 gene polymorphisms as risk factors for rheumatoid arthritis. Human Immunology 77:301–306, 2016 found CC vs TT genotype OR=1.62 (95% CI 1.18–2.22) and C allele vs T allele OR=1.32 (95% CI 1.12–1.54), with the association strongest in Asian populations.

The picture is more nuanced for SLE. A meta-analysis of nine case-control studies (2,544 SLE cases, 3,913 controls)77 meta-analysis of nine case-control studies (2,544 SLE cases, 3,913 controls)
2013 meta-analysis found no significant overall association between the C allele and SLE risk in European or Asian populations, though a single Latin American study showed CC vs TT OR=2.69. The effect appears ethnically heterogeneous, with the strongest and most consistent signals in East Asian populations where it was originally discovered.

Practical Implications

The risk conferred by this variant operates through immune tolerance mechanisms — the balance between B cell activation and Treg suppression — rather than through a specific inflammatory pathway like the cytokine-targeted pathways of PTPN22 or HLA variants. This means the downstream consequences span multiple autoimmune diseases rather than predicting a single condition.

Individuals carrying one or two G alleles (plus-strand) have a biological basis to be more alert to early symptoms of the autoimmune conditions linked to elevated FCRL3: joint stiffness and synovitis (RA), thyroid dysfunction (Graves' disease, Hashimoto's thyroiditis), and systemic symptoms (SLE). The variant does not predict which specific disease will manifest, but it does point toward conditions where impaired B cell tolerance and autoantibody production are central.

Monitoring thyroid function (TSH, free T4) and inflammatory markers periodically is a reasonable approach for GG homozygotes or those with family history of FCRL3-linked conditions.

Interactions

FCRL3 rs7528684 converges on the same B cell activation and tolerance pathway as rs2476601 in PTPN22 (R620W). PTPN22 R620W impairs a phosphatase that normally dampens B cell receptor signalling; elevated FCRL3 from the rs7528684 G allele adds further B cell dysregulation through a different mechanism (NF-κB-driven transcription vs. signalling phosphatase loss). Carriers of both risk variants may have compounded B cell autoreactivity. CTLA4 rs3087243 (CT60) modulates T cell co-inhibition and has been studied alongside FCRL3 in Graves' disease susceptibility in Japanese populations.

Genotype Interpretations

What each possible genotype means for this variant.

AA Lower FCRL3 Expression Normal

Lower baseline FCRL3 expression — typical immune tolerance mechanisms intact

You carry two copies of the A allele (plus-strand) at rs7528684, corresponding to the T allele at the -169 position on the coding strand. This genotype is associated with lower NF-κB-driven FCRL3 transcription in B cells and regulatory T cells, which correlates with more typical B cell activation thresholds and Treg suppressive capacity. About 32% of Europeans carry this genotype. Your risk for FCRL3-linked autoimmune conditions (rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis) is at or below the population average through this particular variant.

AG Intermediate FCRL3 Expression Intermediate

One copy of the higher-expression FCRL3 allele — modestly elevated autoimmune risk

With one copy of the higher-NF-κB-affinity allele, your FCRL3 expression on B cells and regulatory T cells likely falls between that of AA and GG homozygotes. B cells use FCRL3 as a co-receptor that modulates activation signals; elevated expression lowers the threshold for B cell activation and can facilitate autoantibody production. On Tregs, elevated FCRL3 correlates inversely with FOXP3 and IL-35 expression, partially undermining their suppressive role. The heterozygous state suggests a partial rather than maximal effect on immune tolerance.

GG Higher FCRL3 Expression High Risk

Two copies of the higher-expression FCRL3 allele — elevated risk for multiple autoimmune conditions

The GG homozygous genotype results in maximal NF-κB-driven FCRL3 transcription. Functional studies show that CC carriers have higher FCRL3 protein on B cell surfaces and produce greater amounts of autoantibodies compared to TT individuals. On regulatory T cells, elevated FCRL3 correlates with reduced FOXP3 (the master Treg transcription factor) and reduced IL-35 (an anti-inflammatory Treg cytokine), creating a double mechanism for impaired tolerance: more autoreactive B cells and fewer effective suppressors.

The pattern of disease associations — RA, Graves' disease, Hashimoto's thyroiditis, with variable SLE signal — reflects conditions where autoantibodies (rheumatoid factor, anti-CCP, anti-TPO, anti-TSH receptor) are central to pathogenesis. The variant does not predict which specific condition will develop, as that depends on additional genetic (HLA, PTPN22, CTLA4) and environmental factors.

For SLE, the evidence is weaker and ethnically heterogeneous; European SLE studies have not replicated the Asian finding, so SLE risk should not be the primary focus for European carriers.